Haverfield issued the following statement today regarding the proposal to create a potential new drug approval pathway intended to expedite the development of new medicines for serious or life-threatening conditions that would address an unmet medical need, including medicines for serious or life-threatening infections caused by antibiotic-resistant bacteria: